CAS: 198481-32-2; 1-[[4-[2-(Azepan-1-yl)Ethoxy]Phenyl]Methyl]-2-(4-Hydroxyphenyl)-3-Methylindol-5-Ol

该化合物是一种选择性雌激素受体调节器(SERM),主要用于治疗绝经后骨质疏松症.它展示了组织选择性的雌性诱导活动,意思是它在某些组织中可以模仿雌激素,同时阻止其在其他组织中的影响.这个特征使得它有利于骨骼健康,而没有相关的雌性激素治疗风险,例如乳腺癌风险增加.巴泽多克芬通过对骨骼组织中的雌性受体的约束,促进骨密度和减少骨折风险而起作用.它的化学结构包括一个酚类,有助于其受体约束性能.巴泽多克芬通常是口服的,并且往往与治疗疗法中的同源雌激素结合.该物质经过广泛的临床试验,评估其功效和安全概况,表明在改善绝经后妇女骨质矿密度和整体骨质健康方面产生了有利的结果.正如任何药物,潜在副作用和反作用一样,应该加以考虑.它对于病人在开始治疗之前咨询专业人员之前就医至关重要.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号198480-21-6 1-[4-(2-(氮杂环庚烷-... | CAS号1072-21-5 己二醛 | CAS号111-49-9 环己亚胺 | CAS号623-05-2 对羟基苯甲醇 | CAS号35081-45-9 1-[4-(苄氧基)苯基]-2... | CAS号198479-63-9 3-甲基-5-苄氧基-2-(4... | CAS号51388-20-6 4-苄氧基苯胺盐酸盐

合成工艺路线路线简述

  • 合成目标产物 Bazedoxifene 主要起始原料 1-[4-(2-Azepan-1-Yl-Ethoxy)-Benzyl]-5-Benzyloxy-2-(4-Benzyloxy-Phenyl)-3-Methyl-1H-Indole
  • (文献来源)合成步骤主要原料 1-[4-(2-Azepan-1-Yl-Ethoxy)-Benzyl]-5-Benzyloxy-2-(4-Benzyloxy-Phenyl)-3-Methyl-1H-Indole
1-[4-(2-Azepan-1-Yl-Ethoxy)Benzyl]-5-Benzyloxy-2-(4-Benzyloxyphenyl)-3-Methyl-1H-Indole置于10 Wt% Pd(Oh)2 On Carbon Ammonium Formate体系中,用 丙酮 用作溶剂,以85%的收率获得1-[[4-[2-(氮杂环庚烷-1-基)乙氧基]苯基]甲基]-2-(4-羟基苯基)-3-甲基-吲哚-5-醇
参考文献:Processes For The Synthesis Of Bazedoxifene Acetate And Intermediates Thereof
标题:Processes For The Synthesis Of Bazedoxifene Acetate And Intermediates Thereof
摘要:高效合成药用化合物的过程,如(1-[4-(2-Azepan-1-Yl-Ethoxy)-Benzyl]-2-(4-Hydroxy-Phenyl)-3-Methyl-1H-Indol-5-Ol 醋酸,通常称为bazedoxifene 醋酸盐(化学式 Ix),使用公式 Iii 中的氰甲氧基苄卤代物,其中 X=卤素,如 Cl,F,Br,I;G=任何电子给体或电子受体取代基.

海关参考信息

专利信息


专利号:US-11873305-B2
优先权日:2020-06-30
标题 :Processes for synthesis of substituted indole intermediates for the synthesis of serd compounds
发明人:ZHANG HAIMING; XU JIE; WUITSCHIK GEORG; ANGELAUD REMY; HEROLD SEBASTIAN; STUTZ ALFRED; BRUETSCH TOBIAS; BURKHARD JOHANNES
权利人:GENENTECH INC; HOFFMANN LA ROCHE
摘要:Provided herein are processes for the preparation of indolyl intermediates using Wenker Synthesis for the total synthesis of SERD compounds useful in the treatment of cancer.

专利号:US-12383499-B2
优先权日:2018-01-01
标题:Scale up synthesis of silicasome nanocarriers
发明人:NEL ANDRE E; MENG HUAN; LIU XIANGSHENG
权利人:UNIV CALIFORNIA
摘要:In order to facilitate the approval and commercialization of silicasome drug delivery systems (e.g. irinotecan silicasomes) it is necessary to scale up synthesis of the drug-loaded silicasomes. In this regard, it was discovered that the synthesis protocols used for laboratory synthesis of drug-loaded silicasomes (e.g., 500 mg/batch) do not scale to large scale silicasome production, because the resulting products were too heterogeneous for use as pharmaceuticals. Accordingly, new methods are provided herein that effectively afford the large-scale production of mesoporous silica nanoparticles (MSNPs) and lipid bilayer coated MSNPs (silicasomes).

专利号:US-2012253038-A1
优先权日:2009-04-13
标 题:Processes for the synthesis of bazedoxifene acetate and intermediates thereof
发明人:JOSHI SHREERANG; BHUTA SACHIN; TALUKDAR SANJAY; SAWANT SUDHIR; VENKATRAMAN DEEPAK
权利人:JOSHI SHREERANG; BHUTA SACHIN; TALUKDAR SANJAY; SAWANT SUDHIR; VENKATRAMAN DEEPAK; SANDOZ AG
摘要:Efficient processes for the synthesis of pharmaceutically useful compounds such as (1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol acetic acid commonly known as bazedoxifene acetate (Formula IX) using cyanomethoxybenzyl halides of Formula III, where X=Halogens e.g., Cl, F, Br, I; G=Any electron donating or electron withdrawing substituent.

专利号:US-8828984-B2
优先权日:2012-11-19
标题:Gold(III) complexes containing N-heterocyclic carbene ligand, synthesis, and their applications in cancer treatment and thiol detection
发明人:CHE CHI MING; ZOU TAOTAO
权利人:UNIV HONG KONG; UNIV HONG KONG
摘要:Provided herein is a method of synthesis of Au(III)-NHC complexes, a pharmaceutical composition comprises thereof. Also provided herein are the methods for the treatment and prevention of cancer/tumor in patients in need thereof by the administration of the Au(III)-NHC complexes. Also provided is method of detecting thiol in a biological system. The Au(III)-NHC complexes possess anticancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase activity, and inhibition of tumor growth in vivo.

专利号:US-10577387-B1
优先权日:2018-08-09
标题 :Platinum (II) complexes containing N-heterocyclic carbene ligand and pincer ligands, synthesis, and their applications in cancer treatment
发明人:CHE CHI MING; Fung Sin Ki; Chen tian feng
权利人:UNIV HONG KONG
摘要:Provided herein is a method of synthesis of Pt(II) complexes, a pharmaceutical composition comprises thereof. Also provided herein are the methods for the treatment and prevention of cancer/tumor in patients in need thereof by the administration of the Pt(II) complexes. Also provided is a method of detecting the Pt(II) complex in a biological system. Also provided is a method of making the Pt(II) complex The Pt(II) complexes possess anticancer activity such as the induction of cell death, inhibition of cellular proliferation, and inhibition of tumor growth in vivo.

专利号:US-11286271-B2
优先权日:2018-07-31
标 题 :Iridium (III) complexes containing N-heterocyclic carbene ligand, synthesis, and their use thereof in cancer treatment
发明人:CHE CHI MING; LAM TSZ LUNG; TONG KA CHUNG
权利人:UNIV HONG KONG
摘要:Provided herein are Ir(III) complexes comprising N-heterocyclic carbene ligand, method of synthesis of the Ir(III) complexes, a pharmaceutical composition comprises thereof. Also provided herein are the methods for the treatment and prevention of cancer/tumor in patients in need thereof by the administration of the Ir(III) complexes under both dark and light conditions. Also provided is a method of detecting the Ir(III) complex in a biological system. Also provided is a method of making the Ir(III) complex. The Ir(III) complexes possess anticancer activity such as the induction of cell death, inhibition of cellular proliferation, and inhibition of tumor growth in vivo.
上海福之晟生物科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.fzsbio.com
企业联系电话:18049930630,15722522399👤
📞上海福之晟生物科技有限公司 ⚠️参考联系方式
联系人:杨鹏;卞钰麟
电话:18049930630,15722522399
手机:杨鹏18049930630;卞钰麟15722522399
传真:QQ:875507263
邮箱:yangpeng@fzsbio.com;bianyulin@fzsbio.com
通信地址: 上海奉贤区南桥镇杨海路666号
邮编: 201499
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:上海奉贤区南桥镇杨海路666号
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
济南久隆医药科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.jiulongjn.com
企业联系电话:18560096895👤
📞济南久隆医药科技有限公司 ⚠️参考联系方式
联系人:闫经理
电话:18560096895
手机:18560096895

邮箱:18560096895@163.com
通信地址: 山东省济南市高新区春兰路1177号银丰国际生物城B7栋02号
邮编: 250000
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:山东省济南市高新区春兰路1177号银丰国际生物城B7栋02号
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Rzemieniec J, Litwa E, Wnuk A, Lason W, Kajta M. Bazedoxifene and raloxifene protect neocortical neurons undergoing hypoxia via targeting ERα and PPAR-γ. Mol Cell Endocrinol. 2017 Aug 30. pii: S0303-7207(17)30450-1. doi: 10.1016/j.mce.2017.08.014. [Epub ahead of print] doi: 10.1097/GME.0000000000000889. doi: 10.18773/austprescr.2017.039. Epub 2017 May 10. Review.
4: McKeand W. Pharmacokinetics, Dose Proportionality, and Bioavailability of Bazedoxifene in Healthy Postmenopausal Women. Clin Ther. 2017 Sep;39(9):1769-1779. doi: 10.1016/j.clinthera.2017.07.012. Epub 2017 Jul 26. doi: 10.1371/journal.pone.0180297. eCollection 2017.
6: Pinkerton JV, Bushmakin AG, Bobula J, Lavenberg J, Komm BS, Abraham L. Hot flush frequency and severity at baseline as predictors of time to transient and stable treatment success: pooled analysis of two CE/BZA studies. Menopause. 2017 Jun 26. doi: 10.1097/GME.0000000000000918. [Epub ahead of print] doi: 10.1016/j.imbio.2017.05.013. Epub 2017 May 16. doi: 10.1016/j.maturitas.2017.03.315. Epub 2017 Mar 22. doi: 10.1016/j.jsbmb.2017.05.001. Epub 2017 May 4. doi: 10.1097/GME.0000000000000888. doi: CliCa1705723732. Japanese. doi: 10.1136/dtb.2017.4.0466. Review. doi: 10.1016/j.jdiacomp.2016.12.010. Epub 2017 Jan 20. Review.

合成参考文献


参考文献:10.2147/cia.s15711
摘要:Kawate H, Takayanagi R. Efficacy and safety of bazedoxifene for postmenopausal osteoporosis. Clin Interv Aging. 2011;6():151–60.
参考文献:10.1007/s00198-011-1691-1
摘要:Silverman SL, Chines AA, Kendler DL, Kung AWC, Teglbjærg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD, for the Bazedoxifene Study Group. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporosis International. 2011 Jul 21;23(1):351–63. doi: 10.1007/s00198-011-1691-1.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知